Pune, India, January 2018 /MRFR Press Release/- Market Research Future has a half-cooked research report on the global anaplasmosis treatment market.

Anaplasmosis Treatment Market Highlights

Anaplasmosis is a zoonotic disease affecting dogs, cats, livestock, wildlife, and human. It is highly unlikely that a person will contract anaplasmosis from pets directly, but pets could bring ticks with the infection into home, posing a risk to the family. If a pet is diagnosed with anaplasmosis, precautionary measures to reduce the risk of infection. The disease is known as human granulocytic anaplasmosis (HGA) in people, canine granulocytic anaplasmosis in dogs, equine granulocytic anaplasmosis in horses, and tick-borne fever in ruminants.

Favorable government policies for research and the presence of a large number of players in the global anaplasmosis treatment market are the key factors driving the growth of the market during the forecast period.

Anaplasmosis Treatment Regional Analysis

Global anaplasmosis treatment consists of regions namely the Americas, Europe, Asia Pacific, and the Middle East and Africa.

The America is dominating the global anaplasmosis treatment market owing to the high prevalence rate of this disease in the eastern regions. European holds the second largest share of the global anaplasmosis treatment market owing to the increasing research and development in biotechnology and pharmaceutical companies ,especially for study of diagnostic testing.

Asia Pacific is expected to be the fastest growing region and is anticipated to compete with the American market during the forecasted period 2024-2032. Anaplasmosis remains an uncontrolled problem in regions of high endemicity such as the Mediterranean, the Middle East, Africa, Latin America and parts of Asia. The presence of anaplasmosis in India was first established early in the previous century and since then has been reported from almost all states. Furthermore, tick diseases are the most common bacterial laboratory acquired infection worldwide.

Segmentation

The anaplasmosis treatment market is segmented on the basis of species, diagnosis, application, treatment, and end-users.

On the basis of the species, the market is segmented into Deer tick (Ixodes scapularis), western black-legged tick (Ixodes pacificus), Anaplasmosis phagocytophilum or A. platys

On the basis of the diagnosis, the market is segmented into enzyme-linked immunosorbent assay (ELISA), indirect fluorescent antibody (IFA), and polymerase chain reaction (PCR) tests

On the basis of the application, the market is segmented into humans, pets, livestock, wildlife, and others 

On the basis of the treatment, the market is segmented into antibiotics, vaccines, and others. The antibiotics can be further classified as doxycycline, tetracyclines, chlortetracycline, oxytetracycline, rolitetracycline, minocycline and others.

On the basis of the end-user, the market is segmented into hospitals & diagnostic centers, academic institutes, pharmaceutical & biotechnology companies and others.

Key Players

Some of key the players in the global anaplasmosis treatment market are Wyeth Pharmaceuticals (U.S.), Merck Sharp & Dohme (France), Boehringer Ingelheim (France), Bristol-Myers Squibb and Company (U.S.), Glaxosmithkline Inc. (U.S.) Aventis Pharma (Canada), Mylan Pharmaceuticals (U.S.), Pfizer Inc. (U.S.), Teva Pharmaceuticals (Israel), Shire (U.S.), Procter & Gamble, (U.S.), Duramed Pharmaceuticals (U.S.), Takeda Pharmaceuticals (Japan), Ciba Vision (Germany) and Novopharm (Canada).